{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T04:26:08Z","timestamp":1780460768472,"version":"3.54.1"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T00:00:00Z","timestamp":1729814400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jaadcasereports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD Case Reports"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.jdcr.2024.10.013","type":"journal-article","created":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T17:36:05Z","timestamp":1730568965000},"page":"48-50","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Injection site reaction to teclistamab in a patient with multiple myeloma"],"prefix":"10.1016","volume":"56","author":[{"given":"Isabel C.","family":"Yoon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ngan","family":"Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Vazquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Elder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine T.","family":"Steele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misha","family":"Rosenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jdcr.2024.10.013_bib1","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jdcr.2024.10.013_bib2","doi-asserted-by":"crossref","first-page":"308.e1","DOI":"10.1016\/j.jtct.2023.12.016","article-title":"Safety and efficacy of teclistamab in patients with relapsed\/refractory multiple myeloma: a real-world experience","volume":"30","author":"Dima","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"10.1016\/j.jdcr.2024.10.013_bib3","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/s41408-023-00950-3","article-title":"Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis","volume":"13","author":"Chakraborty","year":"2023","journal-title":"Blood Cancer J"},{"issue":"12","key":"10.1016\/j.jdcr.2024.10.013_bib4","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1007\/s00277-023-05451-8","article-title":"Safe and successful teclistamab treatment in very elderly multiple myeloma (MM) patients: a case report and experience from a total of three octogenarians","volume":"102","author":"Dieterle","year":"2023","journal-title":"Ann Hematol"},{"issue":"17","key":"10.1016\/j.jdcr.2024.10.013_bib5","doi-asserted-by":"crossref","first-page":"5539","DOI":"10.3390\/jcm12175539","article-title":"Management of adverse reactions for BCMA-directed therapy in relapsed multiple myeloma: a focused review","volume":"12","author":"Khanam","year":"2023","journal-title":"J Clin Med"},{"issue":"Suppl","key":"10.1016\/j.jdcr.2024.10.013_bib6","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/01.HS9.0000829556.56345.01","article-title":"B04: combination of subcutaneous teclistamab with daratumumab in patients with relapsed\/refractory multiple myeloma (RRMM): results from a phase 1B multicohort study","volume":"6","author":"Rodriguez-Otero","year":"2022","journal-title":"Hemasphere"},{"issue":"Suppl","key":"10.1016\/j.jdcr.2024.10.013_bib7","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/01.HS9.0000936248.01150.e8","article-title":"P30: single cohort results from MajesTEC-2: teclistamab (Tec) in combination with subcutaneous daratumumab (Dara) and lenalidomide (Len) in patients with multiple myeloma (MM)","volume":"7","author":"Searle","year":"2023","journal-title":"Hemasphere"},{"issue":"9","key":"10.1016\/j.jdcr.2024.10.013_bib8","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.jdcr.2024.10.013_bib9","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1080\/10428194.2023.2221756","article-title":"Dermatologic adverse events in acute lymphocytic leukemia patients treated with bispecific T-cell engager blinatumomab","volume":"64","author":"Parisi","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1016\/j.jdcr.2024.10.013_bib10","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/1346-8138.15264","article-title":"Cutaneous adverse events induced by azacitidine in myelodysplastic syndrome patients: case reports and a lesson from published work review","volume":"47","author":"Shimoda-Komatsu","year":"2020","journal-title":"J Dermatol"}],"container-title":["JAAD Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512624004090?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512624004090?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T14:29:16Z","timestamp":1739543356000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352512624004090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":10,"alternative-id":["S2352512624004090"],"URL":"https:\/\/doi.org\/10.1016\/j.jdcr.2024.10.013","relation":{},"ISSN":["2352-5126"],"issn-type":[{"value":"2352-5126","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Injection site reaction to teclistamab in a patient with multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"JAAD Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdcr.2024.10.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}